The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Hodgkin Lymphoma Therapeutics Market Research Report 2025
Synopsis
The global Non-Hodgkin Lymphoma Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Hodgkin Lymphoma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Hodgkin Lymphoma Therapeutics.
Report Scope
The Non-Hodgkin Lymphoma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Hodgkin Lymphoma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Hodgkin Lymphoma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Segment by Type
Chemotherapy
Targeted Therapy
Segment by Application
Clinical Research
Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Hodgkin Lymphoma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Non-Hodgkin Lymphoma Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Hodgkin Lymphoma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Hodgkin Lymphoma Therapeutics.
Report Scope
The Non-Hodgkin Lymphoma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Hodgkin Lymphoma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Hodgkin Lymphoma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Segment by Type
Chemotherapy
Targeted Therapy
Segment by Application
Clinical Research
Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Hodgkin Lymphoma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.3 Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinical Research
1.3.3 Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Hodgkin Lymphoma Therapeutics Market Perspective (2019-2030)
2.2 Non-Hodgkin Lymphoma Therapeutics Growth Trends by Region
2.2.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Non-Hodgkin Lymphoma Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Non-Hodgkin Lymphoma Therapeutics Market Dynamics
2.3.1 Non-Hodgkin Lymphoma Therapeutics Industry Trends
2.3.2 Non-Hodgkin Lymphoma Therapeutics Market Drivers
2.3.3 Non-Hodgkin Lymphoma Therapeutics Market Challenges
2.3.4 Non-Hodgkin Lymphoma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Hodgkin Lymphoma Therapeutics Players by Revenue
3.1.1 Global Top Non-Hodgkin Lymphoma Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Non-Hodgkin Lymphoma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Therapeutics Revenue
3.4 Global Non-Hodgkin Lymphoma Therapeutics Market Concentration Ratio
3.4.1 Global Non-Hodgkin Lymphoma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Therapeutics Revenue in 2023
3.5 Non-Hodgkin Lymphoma Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-Hodgkin Lymphoma Therapeutics Product Solution and Service
3.7 Date of Enter into Non-Hodgkin Lymphoma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Hodgkin Lymphoma Therapeutics Breakdown Data by Type
4.1 Global Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Non-Hodgkin Lymphoma Therapeutics Forecasted Market Size by Type (2025-2030)
5 Non-Hodgkin Lymphoma Therapeutics Breakdown Data by Application
5.1 Global Non-Hodgkin Lymphoma Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Non-Hodgkin Lymphoma Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Hodgkin Lymphoma Therapeutics Market Size (2019-2030)
6.2 North America Non-Hodgkin Lymphoma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2019-2024)
6.4 North America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Hodgkin Lymphoma Therapeutics Market Size (2019-2030)
7.2 Europe Non-Hodgkin Lymphoma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2019-2024)
7.4 Europe Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Hodgkin Lymphoma Therapeutics Market Size (2019-2030)
9.2 Latin America Non-Hodgkin Lymphoma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Introduction
11.1.4 Bristol Myers Squibb Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Non-Hodgkin Lymphoma Therapeutics Introduction
11.2.4 Celgene Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.2.5 Celgene Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Introduction
11.3.4 Eli Lilly Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 F. Hoffman La-Roche
11.4.1 F. Hoffman La-Roche Company Detail
11.4.2 F. Hoffman La-Roche Business Overview
11.4.3 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Introduction
11.4.4 F. Hoffman La-Roche Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.4.5 F. Hoffman La-Roche Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Introduction
11.5.4 GlaxoSmithKline Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Accredo Health Group
11.6.1 Accredo Health Group Company Detail
11.6.2 Accredo Health Group Business Overview
11.6.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Introduction
11.6.4 Accredo Health Group Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.6.5 Accredo Health Group Recent Development
11.7 Baxter International
11.7.1 Baxter International Company Detail
11.7.2 Baxter International Business Overview
11.7.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Introduction
11.7.4 Baxter International Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.7.5 Baxter International Recent Development
11.8 Bayer
11.8.1 Bayer Company Detail
11.8.2 Bayer Business Overview
11.8.3 Bayer Non-Hodgkin Lymphoma Therapeutics Introduction
11.8.4 Bayer Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.8.5 Bayer Recent Development
11.9 Cephalon
11.9.1 Cephalon Company Detail
11.9.2 Cephalon Business Overview
11.9.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Introduction
11.9.4 Cephalon Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.9.5 Cephalon Recent Development
11.10 Eisai Pharmaceuticals
11.10.1 Eisai Pharmaceuticals Company Detail
11.10.2 Eisai Pharmaceuticals Business Overview
11.10.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Introduction
11.10.4 Eisai Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Therapeutics Business (2019-2024)
11.10.5 Eisai Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
